Lentinan: Hematopoietic, immunological, and efficacy studies in a syngeneic model of acute myeloid leukemia

Nutrition and Cancer

Volumn 62, Issue 5, 2010, Pages 574-583

  McCormack, Emmet ^a   Skavland, Joørn ^b   Mujić, Maja ^b   Bruserud, Øystein ^b   Gjertsen, Bjørn Tore ^b  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CYTARABINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IDARUBICIN; INTERLEUKIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; LENTINAN; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE; IMMUNOLOGICAL ADJUVANT;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BROWN NORWAY RAT; CACHEXIA; CANCER PATIENT; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DIET SUPPLEMENTATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; IMMUNOTHERAPY; LEUKOCYTE; LOW DRUG DOSE; MALE; MONOCYTE; MONOTHERAPY; NONHUMAN; NUTRITIONAL VALUE; RAT; STANDARD; TERMINAL DISEASE; WEIGHT GAIN; ANIMAL; BLOOD; BLOOD CELL COUNT; DISEASE MODEL; DRUG EFFECTS; HEMATOPOIESIS; IMMUNOLOGY; LEUKEMIA, MYELOID, ACUTE; TOXICITY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; BLOOD CELL COUNT; CYTOKINES; DISEASE MODELS, ANIMAL; HEMATOPOIESIS; LENTINAN; LEUKEMIA, MYELOID, ACUTE; MALE; RATS; RATS, INBRED BN;

BASIDIOMYCOTA; LENTULA; RATTUS;

EID: 77953976275     PISSN: 01635581     EISSN: None     Source Type: Journal    
DOI: 10.1080/01635580903532416     Document Type: Article

References (47)

1. Mantovani MS, Bellini MF, Angeli JP, Oliveira RJ, Silva AF, et al.: Betaglucans in promoting health: prevention against mutation and cancer. Mutat Res 658, 154-161, 2008.
2. Sullivan R, Smith JE, and Rowan NJ: Medicinal mushrooms and cancer therapy: translating a traditional practice into Western medicine. Perspect Biol Med 49, 159-170, 2006.
3. Cheung NK, Modak S, Vickers A, and Knuckles B: Orally administered beta-glucans enhance anti-tumor effects of monoclonal antibodies. Cancer Immunol Immunother 51, 557-564, 2002.
4. Hong F, Hansen RD, Yan J, Allendorf DJ, Baran JT, et al.: Beta-glucan functions as an adjuvant for monoclonal antibody immunotherapy by recruiting tumoricidal granulocytes as killer cells. Cancer Res 63, 9023-9031, 2003.
5. Hong F, Yan J, Baran JT, Allendorf DJ, Hansen RD, et al.: Mechanism by which orally administered beta-1,3-glucans enhance the tumoricidal activity of antitumor monoclonal antibodies in murine tumor models. J Immunol 173, 797-806, 2004.
6. Mushiake H, Tsunoda T, Nukatsuka M, Shimao K, Fukushima M, et al.: Dendritic cells might be one of key factors for eliciting antitumor effect by chemoimmunotherapy in vivo. Cancer Immunol Immunother 54, 120-128, 2005.
7. Tohamy AA, El-Ghor AA, El-Nahas SM, Noshy MM: Beta-glucan inhibits the genotoxicity of cyclophosphamide, adriamycin, and cisplatin. Mutat Res 541, 45-53, 2003.
8. Nakano H, Namatame K, Nemoto H, Motohashi H, Nishiyama K, et al.: A multi-institutional prospective study of lentinan in advanced gastric cancer patients with unresectable and recurrent diseases: effect on prolongation of survival and improvement of quality of life. Kanagawa Lentinan Research Group. Hepatogastroenterology 46, 2662-2668, 1999.
9. Munemoto Y, Iida Y, Abe J, Saito H, Fujisawa K, et al.: Significance of postoperative adjuvant immunochemotherapy after curative resection of colorectal cancers: association between host or tumor factors and survival. Int J Oncol 20, 403-411, 2002.
10. Ito K, Nakazato H, Koike A, Takagi H, Saji S, et al.: Long-term effect of 5-fluorouracil enhanced by intermittent administration of polysaccharide K after curative resection of colon cancer. A randomized controlled trial for 7-year follow-up. Int J Colorectal Dis 19, 157-164, 2004.
11. Brown GD and Gordon S: Immune recognition of fungal beta-glucans. Cell Microbiol 7, 471-479, 2005.
12. Brown GD: Dectin-1: a signalling non-TLR pattern-recognition receptor. Nat Rev Immunol 6, 33-43, 2006.
13. Willment JA, Marshall AS, Reid DM, Williams DL, Wong SY, et al.: The human beta-glucan receptor iswidely expressed and functionally equivalent to murine Dectin-1 on primary cells. Eur J Immunol 35, 1539-1547, 2005.
14. VetvickaV, Thornton BP and Ross GD: Soluble beta-glucan polysaccharide binding to the lectin site of neutrophil or natural killer cell complement receptor type 3 (CD11b/CD18) generates a primed state of the receptor capable of mediating cytotoxicity of iC3b-opsonized target cells. J Clin Invest 98, 50-61, 1996.
15. Lowenberg B, Downing JR and Burnett A: Acutemyeloid leukemia. N Engl J Med 341, 1051-1062, 1999.
16. Tallman MS, Gilliland DG and Rowe JM: Drug therapy for acute myeloid leukemia. Blood 106, 1154-1163, 2005.
17. Abutalib SA and Tallman MS: Monoclonal antibodies for the treatment of acute myeloid leukemia. Curr Pharm Biotechnol 7, 343-369, 2006.
18. Hatfield KJ, Olsnes AM, Gjertsen BT, and Bruserud O: Antiangiogenic therapy in acute myelogenous leukemia: targeting of vascular endothelial growth factor and interleukin 8 as possible antileukemic strategies. Curr Cancer Drug Targets 5, 229-248, 2005.
19. Bruserud O and Wendelboe O: Biological treatment in acute myelogenous leukaemia: how should T-cell targeting immunotherapy be combined with intensive chemotherapy? Expert Opin Biol Ther 1, 1005-1016, 2001.
20. Jin L, Hope KJ, Zhai Q, Smadja-Joffe F, and Dick JE: Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med 12, 1167-1174, 2006. (Pubitemid 44527352)
21. Tavor S, Petit I, Porozov S, Avigdor A, Dar A, et al.: CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice. Cancer Res 64, 2817-2824, 2004.
22. Weigel BJ, Panoskaltsis-Mortari A, DiersM, Garcia M, Lees C, et al.: Dendritic cells pulsed or fused with AML cellular antigen provide comparable in vivo antitumor protective responses. Exp Hematol 34, 1403-1412, 2006.
23. McCormack E, Bruserud O, and Gjertsen BT: Animal models of acute myelogenous leukaemia-development, application, and future perspectives. Leukemia 19, 687-706, 2005.
24. Gausdal G, Gjertsen BT, McCormack E, Van Damme P, Hovland R, et al.: Abolition of stress-induced protein synthesis sensitizes leukemia cells to anthracycline-induced death. Blood 111, 2866-2877, 2008.
25. Hubeek I, Comijn EM, Van Der Wilt CL, Merriman RL, Padron JM, et al.: CI-994 (N-acetyl-dinaline) in combination with conventional anti-cancer agents is effective against acute myeloid leukemia in vitro and in vivo. Oncol Rep 19, 1517-1523, 2008.
26. Carella AM, Carlier P, Pungolino E, Resegotti L, Liso V, et al.: Idarubicin in combination with intermediate-dose cytarabine and VP-16 in the treatment of refractory or rapidly relapsed patients with acute myeloid leukemia. The GIMEMA Cooperative Group. Leukemia 7, 196-199, 1993.
27. Reagan-Shaw S, Nihal M, and Ahmad N: Dose translation from animal to human studies revisited. FASEB J 22, 659-661, 2008.
28. Saoudi A, Bernard I, Hoedemaekers A, Cautain B, Martinez K, et al.: Experimental autoimmune myasthenia gravis may occur in the context of a polarized Th1- or Th2-type immune response in rats. J Immunol 162, 7189-7197, 1999.
29. Deng G, Lin H, Seidman A, Fornier M, D'Andrea G, et al.: A phase I/II trial of a polysaccharide extract from Grifola frondosa (Maitake mushroom) in breast cancer patients: immunological effects. J Cancer Res Clin Oncol 135, 1215-1221, 2009.
30. Spierings EL, Fujii H, Sun B, and Walshe T: A Phase I study of the safety of the nutritional supplement, active hexose correlated compound, AHCC, in healthy volunteers. J Nutr Sci Vitaminol (Tokyo) 53, 536-539, 2007.
31. Chan L, Hardwick NR, Guinn BA, Darling D, Gaken J, et al.: An immune edited tumour versus a tumour edited immune system: prospects for immune therapy of acute myeloid leukaemia. Cancer Immunol Immunother 55, 1017-1024, 2006.
32. Akimoto M, Ueki H, Nakajima Y, Matano S, Ewasaki H, et al.: Prevention of 5-FU induced toxicity in C3 H/HE mice with interferon or with interferon inducers (poly 1: C, OK-432, Lentinan). Gan To Kagaku Ryoho 11, 1462-1467, 1984.
33. Tamura R, Tanebe K, Kawanishi C, Torii K, and Ono T: Effects of lentinan on abnormal ingestive behaviors induced by tumor necrosis factor. Physiol Behav 61, 399-410, 1997.
34. Iversen PO and Wiig H: Tumor necrosis factor alpha and adiponectin in bone marrow interstitial fluid from patients with acute myeloid leukemia inhibit normal hematopoiesis. Clin Cancer Res 11, 6793-6799, 2005.
35. Kurzrock R: The role of cytokines in cancer-related fatigue. Cancer 92, 1684-1688, 2001.
36. De Benedetti F, Meazza C, and Martini A: Role of interleukin-6 in growth failure: an animal model. Horm Res 58(1 Suppl), 24-27, 2002.
37. Patchen ML, Vaudrain T, Correira H, Martin T, and Reese D: In vitro and in vivo hematopoietic activities of Betafectin PGG-glucan. Exp Hematol 26, 1247-1254, 1998.
38. Cramer DE, Allendorf DJ, Baran JT, Hansen R, Marroquin J, et al.: Betaglucan enhances complement-mediated hematopoietic recovery after bone marrow injury. Blood 107, 835-840, 2006.
39. Chae BJ, Lohakare JD, Moon WK, Lee SL, Park YH, et al.: Effects of supplementation of beta-glucan on the growth performance and immunity in broilers. Res Vet Sci 80, 291-298, 2006.
40. Suzuki M, Kikuchi T, Takatsuki F, and Hamuro J: Curative effects of combination therapy with lentinan and interleukin-2 against established murine tumors, and the role of CD8-positive T cells. Cancer Immunol Immunother 38, 1-8, 1994.
41. Matsuoka H, Seo Y,Wakasugi H, Saito T, and Tomoda H: Lentinan potentiates immunity and prolongs the survival time of some patients. Anticancer Res 17, 2751-2755, 1997.
42. Matsuoka H, Yano K, Seo Y, Saito T, Tomoda H, et al.: Usefulness of lymphocyte subset change as an indicator for predicting survival time and effectiveness of treatment with the immunopotentiator lentinan. Anticancer Res 15, 2291-2296, 1995.
43. Damoiseaux JG, Cautain B, Bernard I, Mas M, van Breda Vriesman PJ, et al.: A dominant role for the thymus and MHC genes in determining the peripheral CD4/CD8 T cell ratio in the rat. J Immunol 163, 2983-2989, 1999.
44. Murata Y, Shimamura T, Tagami T, Takatsuki F, and Hamuro J: The skewing to Th1 induced by lentinan is directed through the distinctive cytokine production by macrophages with elevated intracellular glutathione content. Int Immunopharmacol 2, 673-689, 2002.
45. Hanaue H, Tokuda Y, Machimura T, Kamijoh A, Kondo Y, et al.: Effects of oral lentinan on T-cell subsets in peripheral venous blood. Clin Ther 11, 614-622, 1989.
46. Hong M, Ryan KR, Arkwright PD, Gennery AR, Costigan C, et al.: Pattern recognition receptor expression is not impaired in patients with chronic mucocutanous candidiasis with or without autoimmune polyendocrinopathy candidiasis ectodermal dystrophy. Clin Exp Immunol 156, 40-51, 2009.
47. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, et al.: Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 13, 54-61, 2007. (Pubitemid 46067386)